Thursday, October 9, 2014

hepatitis C combo, gilead


Gilead
AbbVie
Achillion Pharmaceuticals
Merck
J&J
Bristol-Myers Squibb


http://www.bloomberg.com/news/2014-10-07/bristol-myers-gives-up-on-hepatitis-c-combination-in-u-s-.html


http://www.businessinsider.com/r-bristol-myers-pulls-us-marketing-application-for-hep-c-treatment-2014-10

"In late-stage clinical trials, Bristol's two-drug combination cured about 85 percent of patients with 24 weeks of therapy."


http://seekingalpha.com/article/2548255-called-strike-3-for-bristol-myers-squibb-what-this-says-for-gilead-and-its-competitors-in-the-hep-c-market


http://www.nasdaq.com/article/bristol-myers-tells-gilead-sciences-inc-you-win-cm399510

"That decision appears to have worked out for Gilead given that Harvoni's results in phase 3 were almost as good as the Sovaldi and Daklinza combination, with Harvoni clearing the disease in up to 99% of patients."


http://blogs.barrons.com/stockstowatchtoday/2014/10/07/gilead-sciences-here-comes-the-competition/


http://www.bidnessetc.com/26788-gilead-outperforms-biotech-sector-over-success-of-sovaldi-harvoni-and-zydel/1/


http://www.fiercepharma.com/story/sovaldi-may-be-cost-effective-uk-cant-afford-it-documents-say/2014-10-07

"The aggregate cost of treating those patients? Some £1 billion. And that's 'prohibitive,' the NHS briefing documents say (as cited by Pharmafile)."


http://www.fool.com/investing/general/2014/10/07/the-most-important-number-you-need-to-know-before.aspx


http://www.fool.com/investing/general/2014/10/06/johnson-johnson-takes-aim-at-gilead-sciences.aspx


http://seekingalpha.com/article/2539005-the-question-isnt-if-gileads-hep-c-combo-will-be-approved-in-the-us-by-next-friday-the-question-is-the-price-of-the-regimen


http://news.investors.com/technology/041014-696673-merck-hepatitis-drug-combo-could-rival-gilead.htm

"At the International Liver Congress in London, Merck reported a 98% cure rate in patients with hepatitis C genotype 1 who took a combination of its drug candidates MK-5172 and MK-8742."

http://www.dailypharm.com/News/188395

"미국 FDA는 전체가 경구형으로 이뤄진 길리어드의 제품에 대해 오는 10월 10일 최종 승인 결정을 내릴 예정이다. 임상 시험 결과 투여 환자의 99%가 치료 효과를 보여 소발디의 90%보다 높았다."






No comments:

Post a Comment